Backes FJ, Richardson DL, McCann GA, Smith B, Salani R, Eisenhauer EL, Fowler JM, Copeland LJ, Cohn DE, O'Malley DMShould Bevacizumab Be Continued After Progression on Bevacizumab in Recurrent Ovarian Cancer?Int J Gynecol Cancer in press 4/30/2013
Landrum LM, Java J, Mathews CA, Lanneau GS Jr, Copeland LJ, Armstrong DK, Walker JLPrognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study.Gynecol Oncol in press 4/8/2013
McCann GA, Boutsicaris CE, Preston MM, Backes FJ, Eisenhauer EL, Fowler JM, Cohn DE, Copeland LJ, Salani R, O'Malley DMNeuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease.Gynecol Oncol 129(1) 135-9 4/1/2013
Rath KS, Loseth D, Muscarella P, Phillips GS, Fowler JM, O'Malley DM, Cohn DE, Copeland LJ, Eisenhauer EL, Salani ROutcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer.Gynecol Oncol 129(1) 103-6 4/1/2013
McCann GA, Taege SK, Boutsicaris CE, Phillips GS, Eisenhauer EL, Fowler JM, O'Malley DM, Copeland LJ, Cohn DE, Salani RThe impact of close surgical margins after radical hysterectomy for early-stage cervical cancer.Gynecol Oncol 128(1) 44-8 1/1/2013
Seamon LG, Richardson DL, Copeland LJEvolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer.Clin Obstet Gynecol 55(1) 131-55 3/1/2012
Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani REffect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer.Gynecol Oncol 124(2) 221-4 2/1/2012